Literature DB >> 16124985

The occurrence of asymptomatic and symptomatic simple hepatic cysts. A prospective, hospital-based study.

T B Larssen1, J Rørvik, S R Hoff, A Horn, K Rosendahl.   

Abstract

AIM: To examine the prevalence of asymptomatic and symptomatic liver cysts in a university hospital patient population using modern US equipment.
METHODS: Abdominal US scans of 1541 cases referred during the period 21 January to 11 November 2000 were examined for hepatic cysts.
RESULTS: Of 1541 cases, 174 (11.3%) were found to have hepatic cysts, i.e. 109 female (12.5%) and 65 (9.7%) male patients (9.7%). In 413 individuals younger than 40 years, no cysts were found. Above the age of 40 years, prevalence increased with age.
CONCLUSION: By using modern US equipment, we found a higher prevalence of hepatic cysts than that reported in previous studies. Patient selection and the prevalence of liver cysts in the population from which the patients were referred may have influenced our results.

Entities:  

Mesh:

Year:  2005        PMID: 16124985     DOI: 10.1016/j.crad.2005.04.011

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  9 in total

1.  Epidemiology of autosomal-dominant polycystic liver disease in Olmsted county.

Authors:  Tatsuya Suwabe; Alanna M Chamberlain; Jill M Killian; Bernard F King; Adriana V Gregory; Charles D Madsen; Xiaofang Wang; Timothy L Kline; Fouad T Chebib; Marie C Hogan; Patrick S Kamath; Peter C Harris; Vicente E Torres
Journal:  JHEP Rep       Date:  2020-08-04

2.  A Rare SOL of the Liver: Diagnostic and Management Dilemma.

Authors:  Sudeepta Kumar Swain; Tirupporur Govindaswamy Balachandar; Diwaker Sahu; Anand Ramamurthy; Prasanna Kumar Reddy
Journal:  J Clin Diagn Res       Date:  2015-06-01

3.  Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trial.

Authors:  Titus F M Wijnands; Tom J G Gevers; Leo J Schultze Kool; Joost P H Drenth
Journal:  Trials       Date:  2015-03-07       Impact factor: 2.279

4.  Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.

Authors:  Marten A Lantinga; Hedwig M A D'Agnolo; Niek F Casteleijn; Johan W de Fijter; Esther Meijer; Annemarie L Messchendorp; Dorien J M Peters; Mahdi Salih; Edwin M Spithoven; Darius Soonawala; Folkert W Visser; Jack F M Wetzels; Robert Zietse; Joost P H Drenth; Ron T Gansevoort
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

5.  Kidney Injury due to Ureteral Obstruction Caused by Compression from Infected Simple Hepatic Cyst.

Authors:  Naoya Sawada; Tetsu Endo; Kenichiro Mikami; Go Igarashi; Juichi Sakamoto; Hiroshi Tono; Shinsaku Fukuda
Journal:  Case Rep Gastroenterol       Date:  2017-05-19

6.  Long-term safety and efficacy of ethanol retention therapy via percutaneous approach and/or EUS guidance for symptomatic large hepatic cysts (with video).

Authors:  Dong Seok Lee; Sung Koo Lee; Dong-Wan Seo
Journal:  Endosc Ultrasound       Date:  2020 Jan-Feb       Impact factor: 5.628

7.  Predictors of treatment response following aspiration sclerotherapy of hepatic cysts: an international pooled analysis of individual patient data.

Authors:  Titus F M Wijnands; Maxime Ronot; Tom J G Gevers; Julie Benzimra; Leo J Schultze Kool; Valérie Vilgrain; Joost P H Drenth
Journal:  Eur Radiol       Date:  2016-05-14       Impact factor: 5.315

8.  Ethanol sclerotherapy or polidocanol sclerotherapy for symptomatic hepatic cysts.

Authors:  Titus Fm Wijnands; Bastian Schoenemeier; Andrej Potthoff; Tom Jg Gevers; Hans Groenewoud; Michael J Gebel; Kinan Rifai; Michael P Manns; Joost Ph Drenth
Journal:  United European Gastroenterol J       Date:  2018-03-08       Impact factor: 4.623

9.  How much liver does a person need?

Authors:  Igor Alexander Harsch
Journal:  Clin Case Rep       Date:  2019-11-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.